Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis

PPAR Research

Volumn , Issue , 2008, Pages

  Fernandez, Ana Z ^a  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ARACHIDONIC ACID; FENOFIBRATE; FENOPROFEN; FIBRIC ACID DERIVATIVE; FLUFENAMIC ACID; GEMFIBROZIL; GI 2 62570; GW 2331; GW 2433; IBUPROFEN; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; ISOXAZOLIDINE DERIVATIVE; L 796449; LINOLEIC ACID; LINOLENIC ACID; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NETOGLITAZONE; OXIDIZED LOW DENSITY LIPOPROTEIN; PD 72953; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PIRINIXIC ACID; REGLITAZAR; ROSIGLITAZONE; TOMELUKAST; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DIABETES MELLITUS; DISEASE MARKER; ENDOTHELIUM CELL; GENE REPRESSION; HUMAN; HYPERLIPIDEMIA; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; UPREGULATION;

EID: 53149090164     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/285842     Document Type: Review

References (59)

1. Ross R., Atherosclerosis - an inflammatory disease The New England Journal of Medicine 1999 340 2 115 126
2. Chinetti G., Fruchart J.-C., Staels B., Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflammation Research 2000 49 10 497 505
3. Neve B. P., Fruchart J.-C., Staels B., Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis Biochemical Pharmacology 2000 60 8 1245 1250
4. Cuzzocrea S., Pisano B., Dugo L., Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation European Journal of Pharmacology 2004 483 1 79 93
5. Adamiec R., Gacka M., Dobosz T., Szymaniec S., Bednarska-Chabowska D., Sadakierska-Chudy A., Stimulation of the peroxisome proliferator-activated receptorγ (PPARγ) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy Atherosclerosis 2007 194 2 e108 e115
6. Shah P. K., Circulating markers of inflammation for vascular risk prediction: are they ready for prime time Circulation 2000 101 15 1758 1759
7. Chinetti G., Lestavel S., Bocher V., PPAR- α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway Nature Medicine 2001 7 1 53 58
8. Fan Y., Wang Y., Tang Z., Suppression of pro-inflammatory adhesion molecules by PPAR- δ in human vascular endothelial cells Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 2 315 321
9. Lee H., Shi W., Tontonoz P., Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 interleukin-8 by endothelial cells Circulation Research 2000 87 6 516 521
10. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 4 527 550
11. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 1999 99 24 3125 3131
12. Michalik L., Desvergne B., Tan N. S., Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) α and PPAR β mutant mice Journal of Cell Biology 2001 154 4 799 814
13. Akiyama T. E., Lambert G., Nicol C. J., Peroxisome proliferator-activated receptor β / δ regulates very low density lipoprotein production and catabolism in mice on a Western diet The Journal of Biological Chemistry 2004 279 20 20874 20881
14. Gilroy D. W., Colville-Nash P. R., New insights into the role of COX 2 in inflammation Journal of Molecular Medicine 2000 78 3 121 129
15. Tan N. S., Michalik L., Noy N., Critical roles of PPAR β / δ in keratinocyte response to inflammation Genes & Development 2001 15 24 3263 3277
16. Jehl-Pietri C., Bastie C., Gillot I., Luquet S., Grimaldi P. A., Peroxisome-proliferator-activated receptor δ mediates the effects of long-chain fatty acids on post-confluent cell proliferation Biochemical Journal 2000 350 1 93 98
17. Risérus U., Sprecher D., Johnson T., Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 2008 57 2 332 339
18. Oliver W. R. Jr., Shenk J. L., Snaith M. R., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311
19. Debril M.-B., Renaud J.-P., Fajas L., Auwerx J., The pleiotropic functions of peroxisome proliferator-activated receptorγ Journal of Molecular Medicine 2001 79 1 30 47
20. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α andγ are activated by indomethacin and other non-steroidal anti-inflammatory drugs The Journal of Biological Chemistry 1997 272 6 3406 3410
21. Yu K., Bayona W., Kallen C. B., Differential activation of peroxisome proliferator-activated receptors by eicosanoids The Journal of Biological Chemistry 1995 270 41 23975 23983
22. Scher J. U., Pillinger M. H., 15d-PGJ2: the anti-inflammatory prostaglandin? Clinical Immunology 2005 114 2 100 109
23. Schopfer F. J., Lin Y., Baker P. R. S., Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptorγ ligand Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2340 2345
24. Baker P. R. S., Lin Y., Schopfer F. J., Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands The Journal of Biological Chemistry 2005 280 51 42464 42475
25. Baker P. R. S., Schopfer F. J., Sweeney S., Freeman B. A., Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation Proceedings of the National Academy of Sciences of the United States of America 2004 101 32 11577 11582
26. Cunard R., Ricote M., DiCampli D., Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors The Journal of Immunology 2002 168 6 2795 2802
27. Lusis A. J., Atherosclerosis Nature 2000 407 6801 233 241
28. Han K. H., Chang M. K., Boullier A., Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptorγ The Journal of Clinical Investigation 2000 106 6 793 802
29. Galle J., Hansen-Hagge T., Wanner C., Seibold S., Impact of oxidized low density lipoprotein on vascular cells Atherosclerosis 2006 185 2 219 226
30. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell 1998 93 2 229 240
31. Leonarduzzi G., Arkan M. C., Başaǧa H., Chiarpotto E., Sevanian A., Poli G., Lipid oxidation products in cell signaling Free Radical Biology and Medicine 2000 28 9 1370 1378
32. Ricote M., Huang J., Fajas L., Expression of the peroxisome proliferator-activated receptorγ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7614 7619
33. Feng J., Han J., Pearce S. F. A., Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-γ Journal of Lipid Research 2000 41 5 688 696
34. Fischer B., von Knethen A., Brüne B., Dualism of oxidized lipoproteins in provoking and attenuating the oxidative burst in macrophages: role of peroxisome proliferator-activated receptor-γ The Journal of Immunology 2002 168 6 2828 2834
35. Chung S. W., Kang B. Y., Kim S. H., Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor- κ B The Journal of Biological Chemistry 2000 275 42 32681 32687
36. Schreck R., Albermann K., Baeuerle P. A., Nuclear factor κ B: an oxidative stress-responsive transcription factor of eukaryotic cells Free Radical Research Communications 1992 17 4 221 237
37. Schoonbroodt S., Piette J., Oxidative stress interference with the nuclear factor- κ B activation pathways Biochemical Pharmacology 2000 60 8 1075 1083
38. Han C.-Y., Park S.-Y., Pak Y. K., Role of endocytosis in the transactivation of nuclear factor- κ B by oxidized low-density lipoprotein Biochemical Journal 2000 350 3 829 837
39. Price D. T., Loscalzo J., Cellular adhesion molecules and atherogenesis The American Journal of Medicine 1999 107 1 85 97
40. Wang N., Verna L., Chen N.-G., Constitutive activation of peroxisome proliferator-activated receptor-γ suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells The Journal of Biological Chemistry 2002 277 37 34176 34181
41. Hansson G. K., Robertson A.-K. L., Söderberg-Nauclér C., Inflammation and atherosclerosis Annual Review of Pathology 2006 1 1 297 329
42. Marx N., Kehrle B., Kohlhammer K., PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis Circulation Research 2002 90 6 703 710
43. Brånén L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S., Inhibition of tumor necrosis factor- α reduces atherosclerosis in apolipoprotein E knockout mice Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 11 2137 2142
44. Kurebayashi S., Xu X., Ishii S., Shiraishi M., Kouhara H., Kasayama S., A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor- α -induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells Atherosclerosis 2005 182 1 71 77
45. Delerive P., De Bosscher K., Besnard S., Peroxisome proliferator- activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- κ B and AP-1 The Journal of Biological Chemistry 1999 274 45 32048 32054
46. Tedgui A., Mallat Z., Anti-inflammatory mechanisms in the vascular wall Circulation Research 2001 88 9 877 887
47. Jiang C., Ting A. T., Seed B., PPAR-γ agonists inhibit production of monocyte inflammatory cytokines Nature 1998 391 6662 82 86
48. Li A. C., Brown K. K., Silvestre M. J., Willson T. M., Palinski W., Glass C. K., Peroxisome proliferator-activated receptorγ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice The Journal of Clinical Investigation 2000 106 4 523 531
49. Ye Y., Nishi S. P., Manickavasagam S., Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy- Δ 12, 14-PGJ 2 Prostaglandins & Other Lipid Mediators 2007 84 1-2 43 53
50. von Knethen A., Brüne B., Delayed activation of PPARγ by LPS and IFN-γ attenuates the oxidative burst in macrophages The FASEB Journal 2001 15 2 535 544
51. Mallat Z., Besnard S., Duriez M., Protective role of interleukin-10 in atherosclerosis Circulation Research 1999 85 8 e17 e24
52. Thompson P. W., Bayliffe A. I., Warren A. P., Lamb J. R., Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells Cytokine 2007 39 3 184 191
53. Kwak B. R., Myit S., Mulhaupt F., PPARγ but not PPAR α ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells Circulation Research 2002 90 3 356 362
54. Lee C.-H., Chawla A., Urbiztondo N., Liao D., Boisvert W. A., Evans R. M., Transcriptional repression of atherogenic inflammation: modulation by PPAR δ Science 2003 302 5644 453 457
55. Graham T. L., Mookherjee C., Suckling K. E., Palmer C. N. A., Patel L., The PPAR δ agonist GW0742X reduces atherosclerosis in LDLR-/-mice Atherosclerosis 2005 181 1 29 37
56. Barish G. D., Atkins A. R., Downes M., PPAR δ regulates multiple proinflammatory pathways to suppress atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4271 4276
57. Takata Y., Liu J., Yin F., PPAR δ -mediated anti-inflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4277 4282
58. Pascual G., Fong A. L., Ogawa S., A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ Nature 2005 437 7059 759 763
59. Ohshima T., Koga H., Shimotahno K., Transcriptional activity of peroxisome proliferator-activated receptorγ is modulated by SUMO-1 modification The Journal of Biological Chemistry 2004 279 28 29551 29557